OTC Switch Actual Use Studies May Not Be Worth The Expense, Juhl Suggests
This article was originally published in The Tan Sheet
Executive Summary
Actual use studies supporting Rx-to-OTC switch applications provide questionable benefit beyond what is learned in label comprehension studies, according to former Nonprescription Drugs Advisory Committee Chair Randy Juhl, PhD
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning